Current clinical trials of CAR-T therapy against NSCLC and SCLC primarily focus on MSLN, MUC1, GPC3, PSCA, EGFR, CEA, HER2, PD-L1, ROR1, and other promising targets (Table 2). Here, MSLN is linked to non-small cell lung carcinoma.